Health Care https://www.benzinga.com/views/taxonomy/term/140295 en Texas Orthopedic Hospital Recognized as One of the Best Places to Work in Healthcare in 2018 https://www.benzinga.com/pressreleases/18/10/g12537224/texas-orthopedic-hospital-recognized-as-one-of-the-best-places-to-work <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p>Houston, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Texas Orthopedic Hospital was ranked #25 nationally among healthcare providers by Modern Healthcare&#039;s 2018 Best Places to Work in Healthcare, the seventh year in a row it&#39;s been ranked on the list. The complete rankings are <a href="https://www.globenewswire.com/Tracker?data=7RqGZNH853U17LB71CssIzA9pUZuy-negjm1wDe2XyKE0Tk6EkM7pxharEi0-YM5UXn6Z_n_F3rwZGtPDxjq_VVEsvfnvq47y2dnPG2SPxarFvBBiiajbE8IL1MywIvCdFwWxoHYP9P-b_aqh88fr8pIQVcN2dCsXTDUds6JBLdmsAqiAP-phZcbP88XVuAaOg4ZwOP0UG_-Q5cwzak8Vj7vOwdsiHyOM9cNjVuE1_-SXUl6QvumPto-tKVCRgMud2yQEiFUXn7eWiXlTS2-FSuSC1LZYdotLAyrzpNGLKwOkKNsxC8YmeQgtwXDALXDHVd87yQpeSx276Dx0fCVRwLeSdeyqZ0cS0js9orJFIHeTTChb1EnC0kFK_zKJuYPE_OvFdEoAQpqsenaN9T8SkIFRW9oayBXLty0lpy_hUYQerBa1P40WOZ7gQFJ2z6p-vW2PIQ49rv_DPlHdD6jSCF7ucKvE-5jNnHVKj7lzjo=" rel="nofollow" target="_blank" rel="nofollow">available here.</a> Modern Healthcare published a special supplement featuring ranked lists of all the winners with the Oct. 1 issue.<br /><br /></p> <table border="0"> <tr> <td> <table width="305" cellspacing="6" class="gnw_news_media_box" cellpadding="1" border="0"> <tr> <td class="gnw_media_bgcolor"> <table width="100%" align="center" border="0" cellspacing="0" cellpadding="0"> <tr> <td colspan="2"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/494f9064-a8af-4da8-b2c5-3544188ac85e/en" rel="nofollow"><img src="https://resource.globenewswire.com/media/494f9064-a8af-4da8-b2c5-3544188ac85e/medium/" border="0" width="300" height="122" alt="0_medium_TexasOrthopedicHospitalLogo.jpg" /></a></td> </tr> </table> </td> </tr> </table> <p> <br /><br /></p> <table width="305" cellspacing="6" class="gnw_news_media_box" cellpadding="1" border="0"> <tr> <td class="gnw_media_bgcolor"> <table width="100%" align="center" border="0" cellspacing="0" cellpadding="0"> <tr> <td colspan="2"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/d46a4382-f4a8-4b23-b45d-7ba4befdd109/en" rel="nofollow"><img src="https://resource.globenewswire.com/media/d46a4382-f4a8-4b23-b45d-7ba4befdd109/medium/" border="0" width="300" height="122" alt="2_medium_TexasOrthopedicHospitalLogo.jpg" /></a></td> </tr> </table> </td> </tr> </table> <p> <br /><br /> </p></td> </tr> </table> <p>"At Texas Orthopedic Hospital, caring extends to both our patients and our people," said Eric Becker, CEO of Texas Orthopedic Hospital. "Being recognized as one of Modern Healthcare&#039;s Best Places to ...</p><p><a href=https://www.benzinga.com/pressreleases/18/10/g12537224/texas-orthopedic-hospital-recognized-as-one-of-the-best-places-to-work alt=Texas Orthopedic Hospital Recognized as One of the Best Places to Work in Healthcare in 2018>Full story available on Benzinga.com</a></p> Health Care Press Releases Health Care Press Releases Benzinga Fri, 19 Oct 2018 20:44:46 +0000 Globe Newswire 12537224 at https://www.benzinga.com Vital Vio CEO and Co-Founder Colleen Costello Among Goldman Sachs' "100 Most Intriguing Entrepreneurs of 2018" https://www.benzinga.com/pressreleases/18/10/g12536221/vital-vio-ceo-and-co-founder-colleen-costello-among-goldman-sachs-100- <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p>Troy, NY, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE" rel="nofollow">GS</a>) is recognizing <b><a href="https://www.globenewswire.com/Tracker?data=X50LZ9gibE1QaNxDCgXwa7g538dW-zuznCasgNeNsx86YsLNxkTDEqMqW4A0Nv1gwSlEJzJyFBUH33SnDmnZmg==" rel="nofollow" target="_blank" rel="nofollow">Vital Vio</a></b> Co-Founder and CEO Colleen Costello, a pioneer in continuous disinfection technology, as one of the 100 Most Intriguing Entrepreneurs of 2018 at its Builders + Innovators Summit.</p> <table border="0"> <tr> <td> <table width="225" cellspacing="6" class="gnw_news_media_box" cellpadding="1" border="0"> <tr> <td class="gnw_media_bgcolor"> <table width="100%" align="center" border="0" cellspacing="0" cellpadding="0"> <tr> <td colspan="2"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/17b77678-5d91-4bcb-90e0-0c92ca18e823/en" rel="nofollow"><img src="https://resource.globenewswire.com/media/17b77678-5d91-4bcb-90e0-0c92ca18e823/medium/vital-vio-co-founder-and-ceo-colleen-costello-a-pioneer-in-c.jpg" border="0" width="220" height="300" alt="0_medium_CCatGSConf.jpg" /></a></td> </tr> <tr> <td class="gnw_media_caption" width="5"></td> <td align="left" class="gnw_media_caption">Vital Vio Co-Founder and CEO Colleen Costello, a pioneer in continuous disinfection technology, and one of Goldman Sachs&#039; "100 Most Intriguing Entrepreneurs of 2018."</td> </tr> </table> </td> </tr> </table> <p> <br /><br /></p> <table width="305" cellspacing="6" class="gnw_news_media_box" cellpadding="1" border="0"> <tr> <td class="gnw_media_bgcolor"> <table width="100%" align="center" border="0" cellspacing="0" cellpadding="0"> <tr> <td colspan="2"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/01c131f5-1f93-4722-b548-56fe1ec2605d/en" rel="nofollow"><img src="https://resource.globenewswire.com/media/01c131f5-1f93-4722-b548-56fe1ec2605d/medium/" border="0" width="300" height="81" alt="2_medium_vital-vio-wordmark-screen_gradient.png" /></a></td> </tr> </table> </td> </tr> </table> <p> <br /><br /> </p></td> </tr> </table> <p>Goldman Sachs selected Costello as one of 100 entrepreneurs from multiple industries to be honored at the three-day event in Santa Barbara, California</p> <p>"A dynamic economy depends on dynamic entrepreneurs who disrupt industries and occasionally give birth to entirely new sectors," said David M. Solomon, Chief Executive Officer of Goldman Sachs. "The purpose of Builders + Innovators is to support emerging leaders in their quests to innovate faster in order to grow their ideas. We are pleased to recognize Colleen Costello as one of the most intriguing entrepreneurs of 2018."</p> <p>Vital Vio is the healthcare solutions company that has reinvented disinfection with its <b><a href="https://www.globenewswire.com/Tracker?data=k0gexclObRrQ9bANkafLyWvtfvfWkSi6DTNXBcOli8h6m2zYWU4nX2PG5scEzRVg1yZtnGNeqfj71YL6-45l10Oa18cS68UKLIWSYLF1c6WtVI1hKZCfAXfO49bI9TWWyFx4dH-M3LrMZnx5BSJOAnvnpMinTMwDnIzPTRAZyiLzTm-iEp973jCOOouB9ANZbya-_CyJV7Y7f48Iqr6kuhqRLdPcNZKwJCj-uagx86omQl5qniGp04TF9N7NpT_X" rel="nofollow" target="_blank" rel="nofollow">patented</a></b> ...</p><p><a href=https://www.benzinga.com/pressreleases/18/10/g12536221/vital-vio-ceo-and-co-founder-colleen-costello-among-goldman-sachs-100- alt=Vital Vio CEO and Co-Founder Colleen Costello Among Goldman Sachs&#039; &quot;100 Most Intriguing Entrepreneurs of 2018&quot;>Full story available on Benzinga.com</a></p> GS Health Care Restaurants Press Releases General GS US38141G1040 Health Care Restaurants Press Releases General Benzinga Fri, 19 Oct 2018 18:18:45 +0000 Globe Newswire 12536221 at https://www.benzinga.com Nextech to Offer Educational Sessions and EMR Innovations at AAO 2018 https://www.benzinga.com/pressreleases/18/10/g12535774/nextech-to-offer-educational-sessions-and-emr-innovations-at-aao-2018 <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="left">TAMPA, Fla., Oct. 19, 2018 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=ccpzG6J_zgShrjqKwlJD3n5CCKL0KXW608iMV6IVjpxBWE-ArBixGIYr4NDDVqBD2Asxf-u9OCJ-pKHllUf7Jg==" rel="nofollow" target="_blank" rel="nofollow"><u>Nextech Systems</u></a>, a leading provider of healthcare technology solutions for specialty physician practices, including Ophthalmology, will offer multiple educational opportunities in their booth #2262 at the <a href="https://www.globenewswire.com/Tracker?data=x0wKNGSG3jZUJ5DH6J6LM_1W7QJpMV4wLRScuY35YaJX5alPd2Aafh0KOD79zBpVJyR6Y7Z6zZvSZx0xZohQ6E7zWNRxl3BSNnG_R-WigSRA1YtIfZPr4QUmHHVMFhXjdTpJHBfDUOmNhFD0eQ9Y9g==" rel="nofollow" target="_blank" rel="nofollow"><u>American Academy of Ophthalmology Annual Meeting</u></a> (AAO), October 27 – 30 in Chicago, IL. In addition, Nextech will also showcase features and functionalities from its award-winning, cloud-based Electronic Medical Record (EMR), IntelleChartPRO.<br /></p> <p>To better address industry shifts and educate physicians, Nextech will present several educational panel and speaking sessions at AAO addressing topics like compliance and improving patient care. Speakers and panelists include practicing Ophthalmologist and Nextech&#039;s Chief Medical Officer Dr. Dan Montzka, Vice President of Regulatory at Nextech Courtney Tesvich, IntelleChartPRO users and industry experts. Topics will include:</p> <ul type="disc"> <li><strong>Improve Patient Care Leveraging Clinical Efficiency — </strong>Attendees can explore the specific EMR features that can lead ...</li></ul><p><a href=https://www.benzinga.com/pressreleases/18/10/g12535774/nextech-to-offer-educational-sessions-and-emr-innovations-at-aao-2018 alt=Nextech to Offer Educational Sessions and EMR Innovations at AAO 2018>Full story available on Benzinga.com</a></p> News Health Care Press Releases News Health Care Press Releases Benzinga Fri, 19 Oct 2018 17:00:06 +0000 Globe Newswire 12535774 at https://www.benzinga.com Canntab Files Application to Become Licensed Producer https://www.benzinga.com/pressreleases/18/10/g12534603/canntab-files-application-to-become-licensed-producer <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="justify">TORONTO, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Canntab Therapeutics Limited (CSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#CSE" rel="nofollow">PILL</a>) ("<strong>Canntab</strong>" or the "<strong>Company</strong>"), a leader in the development of precision oral dose cannabis tablets and capsules, is pleased to announce that it has filed an application to become a Licensed Producer under the A<em>ccess to Cannabis for Medical Purposes Regulations</em> (the "<strong>License</strong>"), and that it received confirmation from Health Canada that its application had been received. The License, if granted by Health Canada, would allow the Company to process cannabis products at its current production facility in Markham, Ontario with minimal additional capital expenditures as compared to a new purpose-built facility.<br /></p> <p align="justify">"We are excited to announce, as we enter into a new era of legalization, that Canntab has submitted its application to Health Canada to become a Licensed Producer. This is another ...</p><p><a href=https://www.benzinga.com/pressreleases/18/10/g12534603/canntab-files-application-to-become-licensed-producer alt=Canntab Files Application to Become Licensed Producer>Full story available on Benzinga.com</a></p> PILL PILL.CN Health Care Press Releases PILL PILL.CN Health Care Press Releases Benzinga Fri, 19 Oct 2018 14:22:56 +0000 Globe Newswire 12534603 at https://www.benzinga.com Centering® Healthcare Institute Applauds CEO Angie Truesdale, Recognized as TIME Magazine's 50 Most Influential People in Health Care for 2018 https://www.benzinga.com/pressreleases/18/10/g12534059/centering-healthcare-institute-applauds-ceo-angie-truesdale-recognized <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p>Boston, MA, Oct. 19, 2018 (GLOBE NEWSWIRE) -- TIME Magazine named Angie Truesdale, CEO of <a href="https://www.globenewswire.com/Tracker?data=wXNMZZ3lVMPvmNP6azo4cDjMukvqjPtcfl8HUkAmK1ARSWJzPXmFeksoIfBbAn1aWuVonQcFt2GhA9qyq2m5Qq7RcDHBM8YiTOVzRKQmTu2BcU3fPKDKwkGb758zTIcU" rel="nofollow" target="_blank" rel="nofollow">Centering Healthcare Institute</a>, to its first annual list of 50 most influential people in health care. Of the list, TIME editors write, &#34;The American health care system has been plagued for decades by major problems, from lack of access to uncontrolled costs to unacceptable rates of medical errors. And yet, real as those issues remain, the field has also given rise to extraordinary innovation. This year, TIME launched the Health Care 50 to highlight the people behind those ideas: physicians, scientists, and business and political leaders whose work is transforming health care right now.&#34;<br /><br />"It&#039;s an immense honor to be recognized on such an impressive list of health care leaders," said Angie Truesdale, chief executive officer for CHI. "Centering Healthcare Institute has an enormous mission to change health care by harnessing the power of community building and patient voice as part of primary care delivery. It is an organization that is made up of many talented and dedicated people and inclusion on the TIME Health Care 50 is a welcome opportunity to showcase their work and bring more attention to the Centering model."<br /><br />Truesdale joined CHI in 2015 with a charge from the Board of Directors to build upon the foundation created by Centering founder, Sharon Schindler Rising, to scale the model nationally. In a short time, Angie has restructured CHI ...</p><p><a href=https://www.benzinga.com/pressreleases/18/10/g12534059/centering-healthcare-institute-applauds-ceo-angie-truesdale-recognized alt=Centering® Healthcare Institute Applauds CEO Angie Truesdale, Recognized as TIME Magazine&#039;s 50 Most Influential People in Health Care for 2018>Full story available on Benzinga.com</a></p> News Health Care Management Press Releases General News Health Care Management Press Releases General Benzinga Fri, 19 Oct 2018 13:14:00 +0000 Globe Newswire 12534059 at https://www.benzinga.com New Studies Highlight Performance of Vectra® Test in Patients with Rheumatoid Arthritis Who Were Treated with Tofacitinib and Rituximab https://www.benzinga.com/pressreleases/18/10/g12533185/new-studies-highlight-performance-of-vectra-test-in-patients-with-rheu <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="center"><strong>Data Show Vectra Test Is Correlated with Treatment Response</strong><br /></p> <p>SALT LAKE CITY, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ" rel="nofollow">MYGN</a>), a global leader in personalized medicine, today announced new data from two studies of Vectra<sup>®</sup> that evaluated the test&#039;s ability to track treatment response in patients with rheumatoid arthritis (RA).  The studies were conducted by academic collaborators and will be presented at the American College of Rheumatology meeting in Chicago, IL.  The key findings are that Vectra statistically significantly predicted response to tofacitinib and tracked response to rituximab.</p> <p>"We are committed to advancing the knowledge of the Vectra test for rheumatologists and their patients with rheumatoid arthritis.  This year we are highlighting two new studies that demonstrate the performance of Vectra in patients treated with Ritaximab and Tofacitinib," said Elena Hitraya, M.D., Ph.D., chief medical officer, Myriad Autoimmune.  "The goal is to provide rheumatologists with objective molecular information that can enable better patient management."</p> <p>Vectra is the leading personalized medicine test for patients with RA, and it is used to assess changes in disease activity.  In a recently presented analysis based on multiple studies, Vectra was shown to be three times more effective at predicting radiographic progression in patients with RA compared to other measures of disease activity. </p> <p>The key data are summarized below.  Please visit Myriad Autoimmune at Booth #321 to learn more about Vectra.  Follow Myriad on Twitter via @MyriadGenetics and @Vectra and stay informed about conference news and updates by using the hashtag #ACR18.</p> <p><strong>Title:  </strong>Baseline Power Doppler and MBDA Score Predicts 12 Week Disease Activity Response to Tofacitinib.<br /><strong>Presenter:</strong>  Amir Razmjou, M.D., UCLA-David Geffen School of Medicine, Los Angeles, Calif. <br /><strong>Date:</strong>  Sunday, Oct. 21, 2018, 9:00-11:00 a.m. CDT.  <strong> </strong><br /><strong>Abstract Number: </strong>582.</p> <p>This is the first study to evaluate whether baseline Vectra scores were predictive of clinical response in 25 patients with RA who were treated with tofacitinib.  Vectra scores were assessed at baseline, 2 and 12 weeks.  The results show that the Vectra score at baseline was a statistically significant predictor of treatment responses to tofacitinib at week 12 (p&lt;0.01).</p> <p><strong>Title:  </strong>The Multi-Biomarker Disease Activity Score Tracks Response to Rituximab Treatment in Rheumatoid Arthritis Patients.<br /><strong>Presenter:</strong>  Nadia MT Roodenrijs, Ph.D. candidate, University Medical Center Utrecht, the Netherlands. <br /><strong>Date:</strong>  Monday, Oct. 22, 2018, 9:00-11:00 a.m. CDT.  <strong> </strong><br /><strong>Abstract Number: </strong>1500.</p> <p>This is the first study to demonstrate that the Vectra score tracked disease activity in RA patients treated with rituximab and that change in the Vectra score reflected the degree of treatment response.  The Vectra score was measured at baseline (n=57) and at 6 months (n=46).  The results show that the improvement in the Vectra score after 6 months was statistically significant (p&lt;0.01), reflecting response to treatment with rituximab.</p> <p>"We are excited about these new findings which advance the knowledge on Vectra," said Hitraya.  "We&#039;re committed ...</p><p><a href=https://www.benzinga.com/pressreleases/18/10/g12533185/new-studies-highlight-performance-of-vectra-test-in-patients-with-rheu alt=New Studies Highlight Performance of Vectra® Test in Patients with Rheumatoid Arthritis Who Were Treated with Tofacitinib and Rituximab>Full story available on Benzinga.com</a></p> MYGN Health Care Analyst Ratings Press Releases MYGN US62855J1043 Health Care Analyst Ratings Press Releases Benzinga Fri, 19 Oct 2018 11:05:00 +0000 Globe Newswire 12533185 at https://www.benzinga.com Registration is Live for World's Largest Advanced Therapies and Stem Cell Event with 2,000 Attendees Expected at Hyatt Regency Miami in January 2019 https://www.benzinga.com/pressreleases/18/10/g12532809/registration-is-live-for-worlds-largest-advanced-therapies-and-stem-ce <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p>Miami, FL, Oct. 19, 2018 (GLOBE NEWSWIRE) -- The wait is over! Global leaders in advanced therapies, regenerative medicine and the stem cell field can register now for the co-located <a href="https://www.globenewswire.com/Tracker?data=O1PPfrBedgn5r-QtovwplmwqjbvC37Bdi-WMSqf4GzogPTYJvD8oBjYazATm1VkPTZyIAuw0tTWo1fNxs2l5rMO7v_t7r8PZdOn_dUQx2TEKAqipIsEn-9Wtcu4YggCK" rel="nofollow" target="_blank" rel="nofollow">Phacilitate Leaders World</a> and <a href="https://www.globenewswire.com/Tracker?data=NKydAZ8fxYeBQSynHWeqCz9nrJ4lYFKXjVaENZJ0EgPsalYAe7b_EZELHpZ-jJIUrwjOLmXDyN6kY4QLrE-sjfrt_UOLiJQ9_wggT0FBkTvE1VoTFM3dKcW1Dy_J0zaf" rel="nofollow" target="_blank" rel="nofollow">World Stem Cell Summit (WSCS)</a> at the Hyatt Regency Miami, January 22-25, 2019.</p> <table border="0"> <tr> <td> <table width="305" cellspacing="6" class="gnw_news_media_box" cellpadding="1" border="0"> <tr> <td class="gnw_media_bgcolor"> <table width="100%" align="center" border="0" cellspacing="0" cellpadding="0"> <tr> <td colspan="2"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/7062d46e-68ac-4bce-99a1-7d3268ac1f9d/en" rel="nofollow"><img src="https://resource.globenewswire.com/media/7062d46e-68ac-4bce-99a1-7d3268ac1f9d/medium/" border="0" width="300" height="159" alt="0_medium_Imgpg2--10.19.18.png" /></a></td> </tr> </table> </td> </tr> </table> <p> <br /><br /></p> <table width="305" cellspacing="6" class="gnw_news_media_box" cellpadding="1" border="0"> <tr> <td class="gnw_media_bgcolor"> <table width="100%" align="center" border="0" cellspacing="0" cellpadding="0"> <tr> <td colspan="2"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/22babac6-e7e6-42d5-b365-b0978daa3b34/en" rel="nofollow"><img src="https://resource.globenewswire.com/media/22babac6-e7e6-42d5-b365-b0978daa3b34/medium/" border="0" width="300" height="200" alt="2_medium_T7T_9749.jpg" /></a></td> </tr> </table> </td> </tr> </table> <p> <br /><br /></p> <table width="305" cellspacing="6" class="gnw_news_media_box" cellpadding="1" border="0"> <tr> <td class="gnw_media_bgcolor"> <table width="100%" align="center" border="0" cellspacing="0" cellpadding="0"> <tr> <td colspan="2"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/456b538b-5a75-4455-a5ed-4852f57a3b47/en" rel="nofollow"><img src="https://resource.globenewswire.com/media/456b538b-5a75-4455-a5ed-4852f57a3b47/medium/" border="0" width="300" height="67" alt="4_medium_Phacilitate-WSCS.png" /></a></td> </tr> </table> </td> </tr> </table> <p> <br /><br /> </p></td> </tr> </table> <p> </p> <p>Phacilitate and the <a href="https://www.globenewswire.com/Tracker?data=RkMOtw4Q5511bz9Yx93ovbOI1YQnamxmjtGUG3MdqPhN--PogZcHSPnpB0Ekz1tIjDFW_1bL0MqSnNTCzFl7TRcm72ATPMrSJXNPdwmV06WAFC01KrXnZT-FHSCrNCGG" rel="nofollow" target="_blank" rel="nofollow">Regenerative Medicine Foundation (RMF</a>) announced that registration is now open and early bird rates will be available until November 15<sup>th</sup>, 2018. Four meetings within one streamlined partnering event provide senior professionals and stakeholders in cell, gene and immunotherapy new and expanded opportunities for strategic insight and unparalleled business and professional networking. Register now so you do not miss 2019&#039;s largest advanced therapies, transdisciplinary partnering event.</p> <p> </p> <p>New and enhanced opportunities include:</p> <p> </p> <ul> <li><b>Asia Pavilion</b>, where attendees gain strategies for globalization and the essentials of business and regulation in Japan, China and South Korea</li> <li><b>Phacilitate:TALKS</b> will inspire your work long after you leave Miami. Delivered on the exhibition floor without slides, inspiring speakers and leaders will describe the future, including astonishing breakthroughs, species-altering events, amazing technologies and inspiring patient narratives. Hosted by Anemocyte.</li> <li><b>The Clinical Hub</b>, an experiential hub focusing on "big picture" goals: improving patient outcomes and changing the standard of healthcare. Themes include medical economics, patient outcomes, pricing and reimbursement models and patient logistics.</li> <li><b>Ethics and Policy</b>, discussions focused on regulation, registries, standardization, bioethics, societal roadblocks and solutions, all impacting the delivery of lifesaving treatments and cures</li> <li><b>Regenerative Medicine in the Clinic, </b>sessions aimed at ...</li></ul><p><a href=https://www.benzinga.com/pressreleases/18/10/g12532809/registration-is-live-for-worlds-largest-advanced-therapies-and-stem-ce alt=Registration is Live for World&#039;s Largest Advanced Therapies and Stem Cell Event with 2,000 Attendees Expected at Hyatt Regency Miami in January 2019>Full story available on Benzinga.com</a></p> lifestyle Partnerships Health Care Press Releases Health Care Press Releases Benzinga Fri, 19 Oct 2018 10:00:00 +0000 Globe Newswire 12532809 at https://www.benzinga.com Idera Pharmaceuticals Presents Data from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment at the 2018 European Society for Medical Oncology (ESMO) Congress https://www.benzinga.com/pressreleases/18/10/g12532803/idera-pharmaceuticals-presents-data-from-the-illuminate-204-trial-of-t <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="center"><strong>- Key findings presented in poster discussion demonstrate clear abscopal effect of intratumoral tilsotolimod -</strong></p> <p align="center"><strong>- Data demonstrate contribution of tilsotolimod to overcome resistance to ipilimumab in patients with low HLA-ABC expression -</strong></p> <p align="center"><strong>- Company plans to provide additional clinical safety and efficacy data for up to 35 patients during the 4<sup>th</sup> quarter -  </strong></p> <p>EXTON, Pa., Oct. 19, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDRA#NASDAQ" rel="nofollow">IDRA</a>), a clinical-stage biopharmaceutical company focused on the development and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs, today presented data from the ongoing ILLUMINATE-204 trial investigating tilsotolimod, Idera&#039;s intratumorally-delivered toll-like receptor 9 (TLR9) agonist, in combination with ipilimumab (Yervoy®*) at the 2018 European Society for Medical Oncology (ESMO) Congress.</p> <p>The poster, which was selected for a poster discussion session, highlighted additional analyses of data for 21 patients for whom efficacy and safety analysis were originally presented at the 2018 American Society of Clinical Oncology Annual Meeting this past June (data cut-off May 9<sup>th</sup>).</p> <p>The new analyses address the potential of intramural tilsotolimod to induce an antitumor response in combination with ipilimumab in injected tumors as well as uninjected tumors via an abscopal effect. As previously reported the overall response rate (ORR, by RECIST 1.1) for these 21 patients was 39%. Notably, in 7 of the 8 responders tumor shrinkage was observed in both the injected and uninjected tumors. Tumor shrinkage at uninjected lesions was observed in an additional four patients who had not met the criteria for RECIST v.1.1 response status as of this analysis.</p> <p>Clinical responses were seen in patients whose HLA-ABC RNA (MHC class I) expression is low at baseline. Rodig and colleagues<sup>1</sup> have recently shown that robust MHC class I expression is required for anti-CTLA-4 activity. Our findings suggest that combining tilsotolimod with ipilimumab may overcome this resistance mechanism, and therefore, enhance clinical activity and increase the overall response rate compared to that expected with ipilimumab monotherapy.</p> <p>The ILLUMINATE-204 trial is enrolling two distinct patient populations, both patients who are naïve to ipilimumab therapy (N=40; Primary Efficacy Endpoint Population) and patients who have prior ipilimumab experience (N=Up to 20; Secondary Efficacy Endpoint Population). Of the initial 21 patients available for efficacy evaluations 6 of 17 patients from the Primary Efficacy Endpoint Population and 2 of 4 patients from the Secondary Efficacy Endpoint Population achieved RECIST v.1.1 responses, further demonstrating a signal that tilsotolimod has the potential to help overcome prior ipilimumab resistance.</p> <p>"The data presented at ESMO demonstrate that in patients with melanoma progressing on or after PD-1 inhibitor therapy, injecting a single tumor lesion with tilsotolimod, in combination with ipilimumab, produced tumor shrinkage in distant uninjected lesions in nearly all patients with reported responses by RECIST v1.1 criteria," stated Adi Diab, M.D., Lead Trial Investigator, Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center. "Moreover, clinical responses were seen in tumors where MHC class I expression was low at baseline. In a recent clinical study in melanoma, it was shown that robust MHC class I expression is required for anti-CTLA-4 activity. Our findings suggest that combining tilsotolimod with ipilimumab may overcome this mechanism of resistance to anti-CTLA-4 monotherapy."</p> <p>"The clear demonstration of tumor shrinkage in uninjected tumors following the injection of a single tumor lesion with tilsotolimod, ...</p><p><a href=https://www.benzinga.com/pressreleases/18/10/g12532803/idera-pharmaceuticals-presents-data-from-the-illuminate-204-trial-of-t alt=Idera Pharmaceuticals Presents Data from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment at the 2018 European Society for Medical Oncology (ESMO) Congress>Full story available on Benzinga.com</a></p> IDRA News Health Care Press Releases IDRA US45168K3068 News Health Care Press Releases Benzinga Fri, 19 Oct 2018 10:00:00 +0000 Globe Newswire 12532803 at https://www.benzinga.com Corizon Health Helps Raise the Bar on Correctional Healthcare Excellence https://www.benzinga.com/pressreleases/18/10/g12531512/corizon-health-helps-raise-the-bar-on-correctional-healthcare-excellen <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="left"><strong>Company healthcare leaders to present a series of seminars and educational sessions at national conference</strong></p> <table border="0"> <tr> <td> <table width="305" cellspacing="6" class="gnw_news_media_box" cellpadding="1" border="0"> <tr> <td class="gnw_media_bgcolor"> <table width="100%" align="center" border="0" cellspacing="0" cellpadding="0"> <tr> <td colspan="2"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/894ecb7b-b589-4606-9b0e-aa8b2137cd2d/en" rel="nofollow"><img src="https://resource.globenewswire.com/media/894ecb7b-b589-4606-9b0e-aa8b2137cd2d/medium/becky-pinney.jpg" border="0" width="300" height="300" alt="Becky Pinney" /></a></td> </tr> <tr> <td class="gnw_media_caption" width="5"></td> <td align="left" class="gnw_media_caption">Corizon Health Senior Vice President of Nursing Becky Pinney, MSN, RN, CCHP-RN</td> </tr> </table> </td> </tr> </table> <p> <br /><br /> </p></td> </tr> </table> <p>BRENTWOOD, Tenn., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Corizon Health&#039;s correctional healthcare expertise will be on full display at this year&#039;s National Conference of the National Commission on Correctional Health Care (NCCHC), as healthcare professionals from across the company offer a number of important educational sessions designed to help increase the nation&#039;s overall quality and effectiveness of correctional healthcare.</p> <p>Now in its 42<sup>nd</sup> year, the National Conference kicks off Saturday, October 20, in Las Vegas, with two days of preconference seminars, followed by three days of educational sessions. Thousands of correctional healthcare professionals will gather to enhance their knowledge of the unique considerations of delivering health services in correctional and juvenile detention environments.</p> <p>Beginning with the preconference seminar "A Multidisciplinary Approach to Pain Management," sessions taught by Corizon Health leaders will address a range of issues critical to a safe and effective correctional health program including team building, integrated care, chronic disease management, and promoting a healthy work environment to ...</p><p><a href=https://www.benzinga.com/pressreleases/18/10/g12531512/corizon-health-helps-raise-the-bar-on-correctional-healthcare-excellen alt=Corizon Health Helps Raise the Bar on Correctional Healthcare Excellence>Full story available on Benzinga.com</a></p> News Health Care Press Releases News Health Care Press Releases Benzinga Thu, 18 Oct 2018 21:17:26 +0000 Globe Newswire 12531512 at https://www.benzinga.com Natera and Neon Therapeutics Announce Clinical Trial Collaboration to Assess Treatment Response to Personal Cancer Vaccine https://www.benzinga.com/pressreleases/18/10/g12530740/natera-and-neon-therapeutics-announce-clinical-trial-collaboration-to- <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p>Combines Neon&#039;s Personal Neoantigen Vaccine and Signatera (RUO) Circulating Tumor DNA Biomarker in Metastatic Non-Small Cell Lung Cancer Trial<br /></p> <table border="0"> <tr> <td> <table width="164" cellspacing="6" class="gnw_news_media_box" cellpadding="1" border="0"> <tr> <td class="gnw_media_bgcolor"> <table width="100%" align="center" border="0" cellspacing="0" cellpadding="0"> <tr> <td colspan="2"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/2269e5e2-860d-4de6-97ad-3962bda46130/en" rel="nofollow"><img src="https://resource.globenewswire.com/media/2269e5e2-860d-4de6-97ad-3962bda46130/medium/natera-inc-logo.jpg" border="0" width="159" height="45" alt="Natera, Inc. logo" /></a></td> </tr> </table> </td> </tr> </table> <p> <br /><br /> </p></td> </tr> </table> <p align="left">SAN CARLOS, Calif. and CAMBRIDGE, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) --  <a href="https://www.globenewswire.com/Tracker?data=8s1wEFO6M_6c3J1SnTBYICNQ1zD-Fnd4yipHXsI_2RYx8HChEnEqVv_UEnJKLB7dBzn8ZlNftieo3e9MnT3cUg==" rel="nofollow" target="_blank" rel="nofollow">Natera, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ" rel="nofollow">NTRA</a>), a global leader in cell-free DNA testing, and <a href="https://www.globenewswire.com/Tracker?data=Ivr8Zdmq78FEI_-8VGeZogl48dsI9qrXjc4dIcy0fOWxlDhaDwVvb_xegJvRtTNXjejyLhEh7TWe4g0Rt4ZTuLuZxciB3_MrfI7vYpq-aB4=" rel="nofollow" target="_blank" rel="nofollow"><u>Neon Therapeutics, Inc.</u></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTGN#NASDAQ" rel="nofollow">NTGN</a>), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced a research collaboration using Natera&#039;s Signatera™ (RUO) circulating tumor DNA (ctDNA) assay as a biomarker to assess treatment response to NEO-PV-01 in Neon Therapeutics&#039; NT-002 clinical trial. </p> <p>Neon Therapeutics&#039; NT-002 clinical trial is being conducted in collaboration with Merck, also known as MSD outside of the U.S. and Canada, and is designed to evaluate the safety, tolerability, and preliminary efficacy of NEO-PV-01 in combination with KEYTRUDA<sup>®</sup> and a chemotherapy regimen of pemetrexed and carboplatin in untreated patients with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). Natera will utilize its Signatera (RUO) ctDNA assay on patients in this study to correlate treatment response with data from these assays.</p> <p>NEO-PV-01, a personal cancer vaccine, is Neon Therapeutics&#039; most advanced product candidate and is designed specifically for each patient based on tumor-specific DNA mutations. Natera&#039;s Signatera (RUO) assay is a unique approach to deliver a custom ctDNA assay that matches the patient&#039;s tumor profile and is intended to offer high specificity and sensitivity in measuring immunological and clinical treatment response. "This clinical trial is especially exciting for us because, for the very first time, we are combining a truly personal immunotherapy with a personalized ctDNA biomarker to better understand treatment response and resistance in patients with metastatic lung cancer," said Alexey Aleshin, M.D., M.B.A., Natera&#039;s oncology medical director.</p> <p>"We are pleased to apply the Signatera technology to the patient samples that we will be receiving in connection with this clinical trial in order to measure the levels of ctDNA across multiple personal mutations," said Richard Gaynor, M.D., president of research and development at Neon Therapeutics. "We endeavor to employ novel tools in order to develop high-quality treatments for cancer patients and look forward to the information that we will receive from this collaboration."</p> <p><strong>About Signatera <br /> </strong><a href="https://www.globenewswire.com/Tracker?data=8pN1840iXS1cw6mufJqFXVEaugn8YPzQgfLFVHxg6IZ6VaWxBovTtz7frrz2o7i9e7cGI7XJoLG_RMYLrBiwRBq8D25w1y5NZgL6munyChc=" rel="nofollow" target="_blank" rel="nofollow"><u>Signatera (RUO)</u></a> is the first ctDNA assay custom-built for treatment monitoring and minimal residual disease assessment. The Signatera (RUO) methodology differs from currently available liquid biopsy assays, which test for a panel of genes independent of an individual&#39;s tumor. Signatera (RUO) provides each patient ...</p><p><a href=https://www.benzinga.com/pressreleases/18/10/g12530740/natera-and-neon-therapeutics-announce-clinical-trial-collaboration-to- alt=Natera and Neon Therapeutics Announce Clinical Trial Collaboration to Assess Treatment Response to Personal Cancer Vaccine>Full story available on Benzinga.com</a></p> NTGN NTRA Health Care Press Releases General NTRA NTGN Health Care Press Releases General Benzinga Thu, 18 Oct 2018 20:19:52 +0000 Globe Newswire 12530740 at https://www.benzinga.com NewLink Genetics to Host Its Third Quarter 2018 Financial Results Conference Call on November 1, 2018 https://www.benzinga.com/pressreleases/18/10/g12530415/newlink-genetics-to-host-its-third-quarter-2018-financial-results-conf <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p>AMES, Iowa, Oct. 18, 2018 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=zN8CpwtOfkWUeAYRMNoZzAfe5L5p6VjerXWGrlQyVunCjXZp_NjNovfS-Hm2WqRFRnukIa0q1qyMG2NTSTGc6g3RapSz1NfarYNmMC8dbOo5AgGgf1aabPvTHiJQY_eM" rel="nofollow" target="_blank" rel="nofollow">NewLink Genetics Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLNK#NASDAQ" rel="nofollow">NLNK</a>) today announced that it will release its third quarter 2018 financial results on Thursday, November 1, 2018. The company has scheduled a conference call for 4:30 PM ET the same day to discuss the results and to give an update on its clinical development activities.<br /></p> <p>NewLink Genetics&#39; senior management team will host the conference call, which will be open to all listeners. There ...</p><p><a href=https://www.benzinga.com/pressreleases/18/10/g12530415/newlink-genetics-to-host-its-third-quarter-2018-financial-results-conf alt=NewLink Genetics to Host Its Third Quarter 2018 Financial Results Conference Call on November 1, 2018>Full story available on Benzinga.com</a></p> Biotech News NLNK Health Care Press Releases General NLNK News Biotech Health Care Press Releases General Benzinga Thu, 18 Oct 2018 20:01:00 +0000 Globe Newswire 12530415 at https://www.benzinga.com Organization announces Early Career Research Award in the field of celiac disease https://www.benzinga.com/pressreleases/18/10/g12530309/organization-announces-early-career-research-award-in-the-field-of-cel <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p>Philadelphia, PA, Oct. 18, 2018 (GLOBE NEWSWIRE) -- </p><p>Beyond Celiac is announcing the creation of the<b> Society for the Study of Celiac Disease - Beyond Celiac Early Career Research Award</b>, a joint venture to attract exceptionally promising early career academic investigators to the field of celiac disease research. The award will provide a clear and bold opportunity to expand the scope of research in this field that, to date, has been underfunded and underexplored. Beyond Celiac is funding this two-year grant, and SSCD is managing the grant application and research program.<br /><br />The award aims to correct a significant gap in the gastrointestinal and autoimmune disease research portfolio.  Celiac disease consistently received the lowest amount of federal research funding over a five-year period compared to other gastrointestinal conditions, as noted in <a href="https://www.globenewswire.com/Tracker?data=VnRMT2FYXaUeAielFABiLqMj7Pa-xlNMD4ZwG5-uH4JNa9Lx5FoO-imkxfrDKS5nn4-1Hjw_iBWJWjJ7SO8lc2AOwt36X_t4iGkNIApVUD0G59BGF7Tdyjw-dEikMOyD" rel="nofollow" target="_blank" rel="nofollow">a review</a> published as a commentary in the journal <i>Gastroenterology </i>by Emma Clerx, Sonia Kupfer and Daniel A. Leffler. ...</p><p><a href=https://www.benzinga.com/pressreleases/18/10/g12530309/organization-announces-early-career-research-award-in-the-field-of-cel alt=Organization announces Early Career Research Award in the field of celiac disease>Full story available on Benzinga.com</a></p> Health Care Restaurants Press Releases General Health Care Restaurants Press Releases General Benzinga Thu, 18 Oct 2018 19:47:50 +0000 Globe Newswire 12530309 at https://www.benzinga.com Press Briefing on Recent Clinical and Preclinical Advances in Focused Ultrasound https://www.benzinga.com/pressreleases/18/10/g12529859/press-briefing-on-recent-clinical-and-preclinical-advances-in-focused- <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p>Charlottesville, VA, Oct. 18, 2018 (GLOBE NEWSWIRE) -- <br /><br />WHAT: A briefing featuring key data presented at the 6th International Symposium on Focused Ultrasound, the world&#39;s leading forum dedicated to the latest clinical and translational developments in this noninvasive therapy. Researchers and clinicians will highlight breakthrough advances in the use of focused ultrasound in cancer immunotherapy and for opening the blood-brain barrier (BBB).<br /><br />WHEN: Monday, October 22, 2018 </p> <table border="0"> <tr> <td> <table width="305" cellspacing="6" class="gnw_news_media_box" cellpadding="1" border="0"> <tr> <td class="gnw_media_bgcolor"> <table width="100%" align="center" border="0" cellspacing="0" cellpadding="0"> <tr> <td colspan="2"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/698e5f5d-946e-4041-adc9-39905d2686a8/en" rel="nofollow"><img src="https://resource.globenewswire.com/media/698e5f5d-946e-4041-adc9-39905d2686a8/medium/" border="0" width="300" height="89" alt="0_medium_FUFlogo.jpg" /></a></td> </tr> </table> </td> </tr> </table> <p> <br /><br /> </p></td> </tr> </table> <ul> <li>Lunch: 11:30am ET </li> <li>Presentations and Q&amp;A: 12:00 – 1:30pm ET </li> <li>Opportunities for one-on-one meetings with speakers: 1:30 – 2:00pm ET</li> </ul> <p><b>WHERE:</b> Hyatt Regency, 1800 Presidents Street, Reston, Virginia 20190</p> <p><br />To attend in person or arrange for one-on-one interviews with our panelists<b>,</b> contact Wes Myhre at <a href="https://www.globenewswire.com/Tracker?data=3U4ecpMRD2Houdskz5PQPbr7iedsU9XWqqctsOeoZ26gVpCcpvq6D843QchJNeWoip_k7ZggqXgXjqBPh7PnmMji2s6JUvGBYU3ISOdboXc=" rel="nofollow" target="_blank" rel="nofollow"><u>wmyhre@fusfoundation.org</u></a> or 434-284-9285.</p> <p><a href="https://www.globenewswire.com/Tracker?data=qdCmdT58MEsKEI9xEpjZC-8ePIHPrp4gFgqN9jgDA5Y9NcqxeExhmEo6fciwaYSkUhhxiDnMeLmb9bvQ4N1sCAkYe5ccCrP5pfi6wcAOexqOCFgdYnB85R24zqzsA0dTaHbH_QWrmNfcUC5WcmGx8i9iyv9emLElM-qGnCnMfAFYUd6uajEaJ4pIOkDc35KZdgdNxCB18D4sa-8zrGShkAVHjFy7UnRomt4j63fLEyQL2rbTykGH44pKZyLQgRX92k1ubRoK4-yuOB7F2TnPN5UWSjLFunmu8i5Zqo9dUBMwmtEQX8NpS95fq3TmCW3m3aao7XbidRUXyfcbubBQQ9kzeVAIi0deHRzzRjFdZz-NsRFjGLes55tGHFkgjjgDuU4V189G40KFvvGbmKHyrmw8ky-uP9HQHL9YEUjJie3rAq6L2WUD3d4ASZDF70w1usDschGapJYzBPXdkqkpIx4pyfDTtc2cINmq3zkOrEeDs4nyIBwaSc1HYcasRRQt9DZIrGoogzAnBTYndNebH-71v-ETa-3xjoWfBt51g4_m1I8C_bAkhEuvIN57RiFZt2UuBW-NzvyCemu6hBPktsh_F_ergu1I_85nWMBpPJmc629WHJjHisvLsiNBBfHd5tSVEpSiZuZMsNsZqVDGsw==" rel="nofollow" target="_blank" rel="nofollow"><u>Register for webcast</u></a> if unable to attend in person.  </p> <p><b>Featured Speakers and Topics: </b></p> <ul> <li><b>Nathan McDannold, PhD, Associate Professor, Radiology, Harvard Medical School and Brigham &amp; Women&#39;s Hospital</b> <ul> <li>Will discuss the significance of the BBB and the focused ultrasound mechanism for opening it</li> </ul> </li> <li><b>Nir Lipsman, MD, PhD, Neurosurgeon, Sunnybrook Health ...</b></li></ul><p><a href=https://www.benzinga.com/pressreleases/18/10/g12529859/press-briefing-on-recent-clinical-and-preclinical-advances-in-focused- alt=Press Briefing on Recent Clinical and Preclinical Advances in Focused Ultrasound>Full story available on Benzinga.com</a></p> Health Care Press Releases Health Care Press Releases Benzinga Thu, 18 Oct 2018 18:24:49 +0000 Globe Newswire 12529859 at https://www.benzinga.com FDA Advisory Committee Recommends Approval of Shire's Prucalopride (SHP555) for Chronic Idiopathic Constipation https://www.benzinga.com/pressreleases/18/10/g12531657/fda-advisory-committee-recommends-approval-of-shires-prucalopride-shp5 <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p><br /></p> <p><strong>Intended for U.S. Audience <br /> <br /> </strong></p> <p align="center"><strong>FDA Advisory Committee Recommends Approval of Shire&#039;s Prucalopride (SHP555) for Chronic Idiopathic Constipation</strong></p> <p align="center"><em>If FDA grants approval, prucalopride will be the only readily available 5-HT4 receptor agonist</em><sup>1</sup><em> in the U.S. for chronic idiopathic constipation in adults; FDA is anticipated to make a final decision by the end of December </em></p> <p><strong>Cambridge, Mass. – October 18, 2018 </strong>– Shire plc ((LSE: SHP, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPG#NASDAQ" rel="nofollow">SHPG</a>) announced today that the U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee voted unanimously (10 to 0) that the risk-benefit profile of prucalopride supports the approval of this New Drug Application (NDA). The FDA will take the advisory committee&#039;s recommendation into consideration when the agency makes a final determination. The Prescription Drug User Fee Act (PDUFA) action date for prucalopride is December 21, 2018.</p> <p>The advisory committee also voted unanimously (10 to 0) that the potential risk of cardiovascular adverse events with the use of prucalopride in adults with CIC has been adequately addressed by Shire. Prucalopride, a serotonin type 4 (5-HT4) receptor agonist, is a gastrointestinal prokinetic agent that stimulates colonic peristalsis, increasing bowel motility.<sup>2</sup><sup>,[3],[4],[5] </sup>Drugs similar to prucalopride have been associated with adverse cardiovascular (CV) events in the past.</p> <p>"We are pleased with the advisory committee&#039;s vote today supporting prucalopride for the treatment of adults with chronic idiopathic constipation in the U.S., and will continue working with the FDA during the final stages of its review," said Andreas Busch, Ph.D., Head of Research and Development at Shire. "This investigational compound reinforces Shire&#039;s long-standing heritage in gastrointestinal conditions and deep in-house capabilities in the category."</p> <p>Prucalopride has been studied in more than 90 clinical trials worldwide over the last 20 years, including six key studies by which the advisory committee made its recommendation today. The advisory committee reviewed data included in the prucalopride NDA, specifically five main Phase 3 and one Phase 4 double-blind, placebo-controlled clinical trials. An integrated analysis of these six main randomized, controlled clinical trials evaluated the global efficacy and safety of prucalopride 2 mg daily in men and women with chronic constipation; study designs across the trials were similar. Overall, there were 2,484 adult patients included in the integrated efficacy analysis and 2,552 adult patients included in the integrated safety analysis; all patients included received prucalopride less than or equal to 2 mg daily or placebo.<sup>6</sup></p> <p>The committee also reviewed results from an observational, pharmacoepidemiology safety study that Shire sponsored to estimate the risk, as measured by the pooled adjusted incidence rate ratio (IRR), of major adverse CV events (MACE) in adult new users of prucalopride compared to adult new users of polyethylene glycol (PEG). MACE included hospitalization for acute myocardial infarction or stroke and in-hospital CV death. Study data was from real-world settings in the United Kingdom and Sweden. This pooled analysis included over 35,000 patients with chronic constipation treated with prucalopride or PEG in a 1- to- 5 ratio.<sup>7</sup></p> <p>For the observational, pharmacoepidemiology safety study, the pooled adjusted IRR for MACE was 0.64 (95% CI, 0.36, 1.14)<sup>8</sup> in this mostly female (&gt;90%) patient population where many were aged 55 years or younger, which excluded a threefold increase risk of MACE in patients using prucalopride compared with PEG. The average total duration of use was over 170 days for prucalopride and over 80 days for PEG.<sup>7 </sup></p> <p>There are an estimated 35 million adults in the U.S. with chronic idiopathic constipation.<sup>9</sup><sup>,[10]</sup><sup>* </sup>The condition is characterized by difficult, infrequent or incomplete passage of stools over a prolonged period and a range of symptoms, which may include abdominal pain and/or bloating.<sup>11</sup> There are many causes, and one of the possible underlying problems is an impairment or dysfunction of the gut&#039;s ability to move, by contracting and releasing, naturally.<sup>12</sup></p> <p><strong><u>Supporting Clinical Data</u></strong><br />In the integrated analysis of the six main clinical trials, significantly more patients treated with prucalopride versus placebo (27.8% vs 13.2%; p&lt;0.001) achieved an average of three or more spontaneous, complete bowel movements (SCBMs) per week over the 12-week treatment period. The most common (greater than or equal to 5%) treatment-emergent adverse events (TEAEs) in the prucalopride group were diarrhea, headache, abdominal pain, and nausea. ...</p><p><a href=https://www.benzinga.com/pressreleases/18/10/g12531657/fda-advisory-committee-recommends-approval-of-shires-prucalopride-shp5 alt=FDA Advisory Committee Recommends Approval of Shire&#039;s Prucalopride (SHP555) for Chronic Idiopathic Constipation>Full story available on Benzinga.com</a></p> SHPG Health Care Press Releases SHPG Health Care Press Releases Benzinga Thu, 18 Oct 2018 17:44:05 +0000 Globe Newswire 12531657 at https://www.benzinga.com Syapse Hosts Inaugural Precision Medicine Council to Drive Progress in Precision Oncology https://www.benzinga.com/pressreleases/18/10/g12529318/syapse-hosts-inaugural-precision-medicine-council-to-drive-progress-in <link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="left"><strong>Nation&#039;s leading health systems convene today to share best practices and improve cancer care</strong><br /></p> <p>SAN FRANCISCO, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Syapse, the leading precision medicine company, is convening innovative health systems today in San Francisco for the inaugural Syapse Precision Medicine Council, a group of healthcare leaders dedicated to advancing precision oncology through sharing best practices.</p> <p>For the next two days, 35 participants from more than a dozen health systems from across the United States and South Korea will share strategies and insights for growing precision medicine programs and ensuring that more people have access to molecular tests and clinical trials.</p> <p>"We formed the Syapse Precision Medicine Council to facilitate the exchange of concrete lessons and build on the rapid progress and growth of precision medicine," said Ken Tarkoff, CEO of Syapse. "Today, I am thrilled that we are taking the next step by coming together in San Francisco and working to give all patients ...</p><p><a href=https://www.benzinga.com/pressreleases/18/10/g12529318/syapse-hosts-inaugural-precision-medicine-council-to-drive-progress-in alt=Syapse Hosts Inaugural Precision Medicine Council to Drive Progress in Precision Oncology>Full story available on Benzinga.com</a></p> Health Care Press Releases Health Care Press Releases Benzinga Thu, 18 Oct 2018 17:00:00 +0000 Globe Newswire 12529318 at https://www.benzinga.com